Acute Myeloid Leukaemia Clinical Trial
Official title:
Phase I, Open Label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of Multiple Infusions of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor) in Patients With Adverse Genetic Risk Acute Myeloid Leukaemia
This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine the Maximum Tolerated Dose (MTD).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02272478 -
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
|
Phase 2/Phase 3 | |
| Completed |
NCT03672695 -
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
|
Phase 1 | |
| Completed |
NCT01019161 -
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)
|
Phase 1 | |
| Completed |
NCT00530699 -
Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
|
Phase 1 | |
| Not yet recruiting |
NCT06326697 -
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
|
Phase 1 | |
| Active, not recruiting |
NCT01597219 -
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
|
Phase 2 | |
| Completed |
NCT01063660 -
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
|
Phase 2 | |
| Terminated |
NCT05712278 -
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Terminated |
NCT03217838 -
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
|
Phase 1 | |
| Active, not recruiting |
NCT04217278 -
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
|
Phase 2/Phase 3 | |
| Completed |
NCT02844257 -
Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia
|
N/A | |
| Active, not recruiting |
NCT01716364 -
Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT06345365 -
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
|
Phase 3 | |
| Completed |
NCT01422603 -
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04629443 -
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02189824 -
Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT02724163 -
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
|
Phase 3 | |
| Completed |
NCT01621724 -
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
|
Phase 1/Phase 2 | |
| Completed |
NCT01236144 -
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
|
Phase 1/Phase 2 | |
| Completed |
NCT01497002 -
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a
|
Phase 3 |